Summit Therapeutics (SMMT)
Develops Akeso-origin ivonescimab through multinational late-stage oncology trials.
$16.96
vs last close−0.16 (−0.91%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 17.16% | 136.89M shares | |
|---|---|---|---|
| 269 holders · as of Jun 30, 2026 | |||
| Insiders | 75.59% | 602.99M shares | |
| 3 holders · as of Jun 12, 2026 | |||
| Other | 7.25% | 57.87M shares | |
| remainder | |||
797.75M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
269 holders · 136.89M shares · 60 new positions · 158 increased · 60 reduced · 37 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 32.79M | 4.11% | −3.60M | Aug 14, 2026 |
| FMR LLC | 10.04M | 1.26% | −809.3K | Aug 13, 2026 |
| State Street Corp | 9.54M | 1.20% | +2.51M | Aug 7, 2026 |
| BlackRock, Inc. | 9.53M | 1.19% | −124.7K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 5.73M | 0.72% | +22.7K | Aug 13, 2026 |
| UBS Group AG | 5.23M | 0.66% | +1.55M | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 5.04M | 0.63% | −191.1K | Aug 13, 2026 |
| Goldman Sachs Group Inc | 4.51M | 0.57% | +4.20M | Aug 14, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 12, 2026 | Robert W. Duggandirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 3,810,000 | $13.12 | 573,883,879 |
| Jun 12, 2026 | Mahkam Zanganehdirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 3,810,000 | $13.12 | 573,883,879 |
| Jun 4, 2026 | Manmeet Singh Sonidirector, officer: COO and CFO | Purchase · 2 lots | 50,000 | $14.45 | 3,123,603 |
| Jun 4, 2026 | Mahkam Zanganehdirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 100,000 | $14.60 | 25,824,474 |
| Jun 4, 2026 | Robert W. Duggandirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 100,000 | $14.60 | 25,824,474 |
| Oct 21, 2025 | Mahkam Zanganehdirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 26,680 | $18.74 | 76,680 |
| Oct 21, 2025 | Robert W. Duggandirector, 10 percent owner, officer: Co-Chief Executive Officer | Purchase | 26,680 | $18.74 | 76,680 |
| Oct 21, 2025 | Yu Xiadirector | Purchase | 533,617 | $18.74 | 32,057,147 |
House and Senate disclosures
Not reported.